AngioDynamics buys Oncobionic
This article was originally published in The Gray Sheet
Privately held irreversible electroporation (IRE) soft tissue ablation technology developer Oncobionic is acquired by AngioDynamics. The deal is valued at up to $25 mil. - including $5 mil. up-front and up to $20 mil. in milestone payments. Announced Oct. 17, the agreement builds on the firms' 2004 distribution and option pact for the IRE device. Trials for liver and prostate cancer are slated to begin in mid-2007, followed by a market launch in 2008. A 510(k) application is pending at FDA for use in general tissue ablation. IRE uses needles, an electrical field and image guidance to disrupt targeted cell membranes without causing thermal damage, firm says...
You may also be interested in...
AngioDynamics will gain immediate access to the targeted tumor ablation market and will fill out its vascular access business in a $220 mil. acquisition of Rita Medical
Butterfly Network chose SPAC route with Longview Acquisition Corp. to scale its business and expand into the home market in 2021.
Regulatory review resource-intensive cell and gene therapy licensing applications are rolling toward US FDA along expedited pathways, while complete response letters and missed goal dates start to stack up under pandemic inspection constraints.